Immuno-oncology

all catalysts(0)

nothing on the calendar yet

News(9)

• Ensoma sheds more staff, pauses preclinical programs to home in on lead gene therapy
  Boston biotech Ensoma is doubling down on its lead gene therapy for a rare immune disease, laying off another round of employees after previously halving its workforce last November.
  fiercebiotech · 4d ago
• LifeMine raises $263M in mission to improve organ transplant aftercare
  Patients who receive an organ transplant must take difficult immuno-suppressive medicines for the rest of their lives. LifeMine Therapeutics wants to offer a safer alternative.
  biospace · 5d ago
• ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
  If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
  biospace · 8d ago
• Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
  After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…
  fiercebiotech · 13d ago
• Summit, Merck must navigate new regulatory terrain in China-first cancer landscape
  Summit Therapeutics revealed positive Western data last week from a Phase 3 trial of lung cancer candidate ivonescimab. In a flipped geographical clinical trials landscape, what more will be requir…
  biospace · 16d ago
• Summit has less than a year of cash runway left as PD-1/VEGF verdict nears
  Summit’s star asset is the PD-1/VEGF bispecific ivonescimab, which this week produced promising survival data from a late-stage global trial in non-small cell lung cancer. The FDA review is ongoing…
  biospace · 18d ago
• Summit and Akeso sharpen case for ivonescimab with new Western data
  Summit Therapeutics and Akeso are answering questions raised about ivonescimab’s ability to translate to Western populations, though the partners have yet to share if the new findings are statistic…
  biospace · 20d ago
• Kelun’s Merck-partnered ADC notches late-stage NSCLC win alongside Keytruda
  The Phase 3 results are the first direct proof-of-concept for an ADC replacing platinum-based chemo in a first-line standard-of-care regimen for non-small cell lung cancer, according to Leerink Par…
  biospace · 27d ago
• Track the Lung Cancer Abstracts That are Gaining Attention at ASCO 2026
  Read on to see what data are poised to shape clinical discussions and decision-making in lung cancer at 2026 ASCO Annual Meeting in Chicago, Illinois.
  onclive · 3mo ago